Here's Why GlycoMimetics Is Soaring 24.3% Higher Today

Here's Why GlycoMimetics Is Soaring 24.3% Higher Today

After unveiling updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML), GlycoMimetics (NASDAQ: GLYC) shares are surging 24.3% as of noon EST Tuesday.

In June, GlycoMimetics provided results for GMI-1271 at the American Society of Clinical Oncology (ASCO) annual meeting. At the time, results from this phase 1/2 study failed to impress, causing shares to sell-off.

Image source: Getty Images.

Continue reading

Source: Fool.com